Arrowhead Doses First Subjects in ARO-DIMER-PA Clinical Trial
Arrowhead announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's investigational RNA interference therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 and apolipoprotein C3 genes.
